PMID- 22069289
OWN - NLM
STAT- MEDLINE
DCOM- 20120325
LR  - 20131121
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
VI  - 27
IP  - 8
DP  - 2011 Nov
TI  - The effect of vitamin D supplementation on peripheral regulatory T cells and beta 
      cell function in healthy humans: a randomized controlled trial.
PG  - 942-5
LID - 10.1002/dmrr.1276 [doi]
AB  - BACKGROUND: Increasing evidence supports the role of vitamin D (vitD) in 
      modifying the risk to develop type 1 diabetes (T1D) and other autoimmune 
      diseases. VitD3 might stimulate regulatory T cells (Tregs), a central player in 
      the maintenance of self-tolerance. In addition, direct effects of vitD on beta-cell 
      function are postulated. The aim of our study was to evaluate the effect of a 
      high dose vitD supplementation on Tregs frequency (%Tregs) and beta-cell function 
      assessed by a mixed meal tolerance test (MMTT) in healthy humans. METHODS: A 
      double-blind, placebo controlled trial was performed in 59 healthy adult subjects 
      (49% females). Subjects received oral vitD3 (140,000 IU monthly) or placebo for 3 
      months. %Tregs within 20,000 CD4+ T cells of peripheral blood was determined by 
      multi-parametric FACS-analysis. A liquid MMTT was carried out before and after 
      treatment. RESULTS: %Tregs increased significantly in the vitD group, but 
      remained unchanged in the placebo group. Fasting C-peptide concentrations did not 
      change significantly in either group. Similarly, the mean AUC for C-peptide after 
      3 months and the change in mean values from baseline to the end of the treatment 
      were comparable in both groups. CONCLUSIONS: A short time high dose vitD3 
      supplementation significantly increased the frequency of Tregs, but did not 
      further improve beta-cell function in apparently healthy subjects. The 
      immunomodulatory potential of vitD might be an important mechanistic link for the 
      association of vitD and T1D.
CI  - Copyright (c) 2011 John Wiley & Sons, Ltd.
FAU - Bock, Gerlies
AU  - Bock G
AD  - Department of Endocrinology and Metabolism, Medical University of Graz, Graz, 
      Austria. gerlies.bock@medunigraz.at
FAU - Prietl, Barbara
AU  - Prietl B
FAU - Mader, Julia K
AU  - Mader JK
FAU - Holler, Evelyne
AU  - Holler E
FAU - Wolf, Michael
AU  - Wolf M
FAU - Pilz, Stefan
AU  - Pilz S
FAU - Graninger, Winfried B
AU  - Graninger WB
FAU - Obermayer-Pietsch, Barbara M
AU  - Obermayer-Pietsch BM
FAU - Pieber, Thomas R
AU  - Pieber TR
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
RN  - 0 (C-Peptide)
RN  - 1C6V77QF41 (Cholecalciferol)
SB  - IM
MH  - Adult
MH  - C-Peptide/blood
MH  - Cholecalciferol/administration & dosage/*therapeutic use
MH  - Dietary Supplements
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Immunomodulation/drug effects/physiology
MH  - Insulin-Secreting Cells/drug effects/*physiology
MH  - T-Lymphocytes, Regulatory/*drug effects
EDAT- 2011/11/10 06:00
MHDA- 2012/03/27 06:00
CRDT- 2011/11/10 06:00
PHST- 2011/11/10 06:00 [entrez]
PHST- 2011/11/10 06:00 [pubmed]
PHST- 2012/03/27 06:00 [medline]
AID - 10.1002/dmrr.1276 [doi]
PST - ppublish
SO  - Diabetes Metab Res Rev. 2011 Nov;27(8):942-5. doi: 10.1002/dmrr.1276.